EFM
CRVS icon

E Fund Management’s Corvus Pharmaceuticals CRVS Stock Holding History

E Fund Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$207K Buy
+14,156
New +$226K 0.01% 447

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

E Fund Management's CRVS Position: Q1 2026 in Review

E Fund Management opened a new position in Corvus Pharmaceuticals (CRVS) in Q1 2026: 14,156 shares worth $207K. The stake represents 0.01% of the portfolio and ranks #447 among its holdings.

164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • E Fund Management held 14,156 shares of Corvus Pharmaceuticals worth $207K as of Q1 2026.
  • Corvus Pharmaceuticals was a new E Fund Management position in Q1 2026.
  • Corvus Pharmaceuticals made up 0.01% of E Fund Management's portfolio in Q1 2026, its #447 holding.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on E Fund Management's 13F filing for Q1 2026, filed 13 Apr 2026.